Furthermore, pancreatic cancer patients with lower METTL3, METTL14, RBMX, FTO, ALKBH5, YTHDF1, and YTHDC1 mRNA expression levels or higher VIRMA, HNRNPA2B1, EIF3A, IGF2BP1, IGF2BP2, and IGF2BP3 mRNA expression levels had significantly poorer OS (P < 0.05, Fig. 6C, D). This evidence concerns the gene METTL3 and pancreatic neoplasm.